Adaptive Biotechnologies Company Insiders

Adaptive Biotechnologies Management Team Effectiveness

Adaptive Biotechnologies has return on total asset (ROA) of (0.1395) % which means that it has lost $0.1395 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.3752) %, meaning that it created substantial loss on money invested by shareholders. Adaptive Biotechnologies management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. Return on Investment is likely to gain to 17.98 in 2023, whereas Return on Average Assets are likely to drop (0.26)  in 2023. Total Liabilities is likely to drop to about 349.6 M in 2023. Current Liabilities is likely to drop to about 101.3 M in 2023Issuance Purchase of Equity Shares is likely to gain to about 8.1 M in 2023, whereas Weighted Average Shares is likely to drop slightly above 124 M in 2023.

Adaptive Biotechnologies Workforce Comparison

Adaptive Biotechnologies Profit Margins

The company has Profit Margin (PM) of (1.08) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.07) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.07.

Adaptive Biotechnologies Insider Trading

Adaptive Biotechnologies Benchmark Summation

Adaptive Biotechnologies Notable Stakeholders

The success or failure of an entity such as Adaptive Biotechnologies often depends on how effective the management is. Adaptive Biotechnologies management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Adaptive management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Adaptive management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

The data published in Adaptive Biotechnologies' official financial statements usually reflect Adaptive Biotechnologies' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Adaptive Biotechnologies. For example, before you start analyzing numbers published by Adaptive accountants, it's critical to develop an understanding of what Adaptive Biotechnologies' liquidity, profitability, and earnings quality are in the context of the Life Sciences Tools & Services space in which it operates.

Please note, the presentation of Adaptive Biotechnologies' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Adaptive Biotechnologies' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Adaptive Biotechnologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Adaptive Biotechnologies Corp. Please utilize our Beneish M Score to check the likelihood of Adaptive Biotechnologies' management to manipulate its earnings.

Today, most investors in Adaptive Biotechnologies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Adaptive Biotechnologies' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's per employee growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Adaptive Biotechnologies per employee as a starting point in their analysis.

Check out Trending Equities. For more information on how to buy Adaptive Stock please use our How to Invest in Adaptive Biotechnologies guide. You can also try Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

When running Adaptive Biotechnologies price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.

Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine Adaptive Biotechnologies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.